Dr. Reddy’s Laboratories gets Health Canada nod for generic Semaglutide injection

Dr. Reddy's Laboratories received a Notice of Compliance (NOC) from Health Canada on April 29, 2026, for a generic version of semaglutide injection — the act...

What Happened

Dr. Reddy's Laboratories received a Notice of Compliance (NOC) from Health Canada on April 29, 2026, for a generic version of semaglutide injection — the active ingredient in Ozempic (diabetes) and Wegovy (obesity).
This makes Canada the first G7 country to approve a generic semaglutide, and Dr. Reddy's the first company globally to receive such approval in a G7 market.
The approval covers semaglutide injection in two dosage forms: 2 mg/pen (1.34 mg/mL) and 4 mg/pen (1.34 mg/mL).
Novo Nordisk lost Canadian patent protection for semaglutide after missing a patent maintenance fee, opening the market to generic competition ahead of US and European timelines.
Generic semaglutide is expected to cost approximately ₹3,400–₹6,700/month in Canada (CAD 40–80), versus CAD 450 for branded Ozempic — a potential 80–90% price reduction.

Static Topic Bridges

GLP-1 Receptor Agonists: Mechanism and Therapeutic Significance

Semaglutide belongs to the class of GLP-1 receptor agonists (GLP-1 RAs) — drugs that mimic the action of glucagon-like peptide-1, a naturally occurring hormone secreted by intestinal cells after meals. GLP-1 stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and signals satiety to the brain. These combined effects lower blood glucose, reduce appetite, and produce sustained weight loss — making GLP-1 RAs a breakthrough therapy for both type 2 diabetes and obesity.

GLP-1 receptor agonists: incretin-based therapy; approved drugs include semaglutide, liraglutide, dulaglutide, and tirzepatide.
Ozempic (semaglutide, injectable): approved for type 2 diabetes management; weekly injection.
Wegovy (semaglutide, higher dose): approved for chronic weight management in obesity.
Rybelsus: oral formulation of semaglutide for type 2 diabetes.
Clinical trials show semaglutide reduces body weight by 12–15% on average and significantly reduces cardiovascular event risk.
Type 2 diabetes affects over 100 million adults in India — the world's diabetes capital — making affordable GLP-1 RA access a public health priority.

Connection to this news: Dr. Reddy's approval for a generic GLP-1 RA signals the beginning of democratised access to the world's most in-demand class of drugs — with direct implications for India's own healthcare access policy and export potential.

India's Pharmaceutical Industry: Generic Drug Leadership

India is the world's largest supplier of generic medicines by volume, providing approximately 20% of global generic drug exports. The Indian pharmaceutical sector exports to over 200 countries, is the largest supplier of vaccines to UNICEF, and is the single largest supplier to the US FDA-regulated generic drug market. This position was built on a combination of strong chemistry expertise, affordable manufacturing, and a post-1970 patent regime that prioritised public health over intellectual property exclusivity.

India's pharma exports: approximately USD 30.38 billion in FY25.
India supplies 55–60% of UNICEF's vaccine requirements and 45% of US generic drug demand by volume.
India is the largest manufacturer of WHO-prequalified generic medicines.
Key challenge: India imports ~70% of its Active Pharmaceutical Ingredients (APIs) from China, creating supply chain vulnerability.
Government response: PLI scheme for bulk drugs/APIs (₹6,940 crore) to build domestic API manufacturing capability.
Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS) aligns Indian manufacturing with WHO-GMP standards.
Drugs (Prices Control) Order (DPCO) governs essential medicine pricing in India; administered by NPPA (National Pharmaceutical Pricing Authority).

Connection to this news: Dr. Reddy's achieving a "first-in-G7" generic approval for semaglutide demonstrates Indian pharma's capability to compete at the frontier of complex biologics-adjacent drugs — moving beyond small-molecule generics — and reinforces India's strategic position as the "pharmacy of the world."

Intellectual Property, Patent Cliffs, and Generic Drug Access

Patent expiry events ("patent cliffs") are among the most consequential moments in global pharmaceutical markets — they determine when affordable generic competition can begin. Under the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights), WTO member countries must provide at least 20 years of patent protection for pharmaceutical innovations. When a patent expires or lapses, generic manufacturers can enter the market, dramatically reducing drug prices and expanding access. The TRIPS Agreement also includes flexibilities — compulsory licensing and parallel imports — that allow developing countries to override patents for public health emergencies.

TRIPS Agreement (1994): Part of WTO framework; mandates 20-year patent protection; includes public health flexibilities (Doha Declaration, 2001).
Doha Declaration on TRIPS and Public Health (2001): Affirmed that TRIPS flexibilities include issuing compulsory licences for medicines needed to address public health crises.
India's Patents Act, 1970 (amended 2005): Section 3(d) prevents "evergreening" — the practice of extending patent protection through minor modifications to existing drugs.
Section 84, Patents Act: Provisions for compulsory licensing in India (used for Sorafenib/Nexavar in 2012 — India's first compulsory licence).
In this case: Novo Nordisk's Canadian patent lapsed due to a missed maintenance fee — not a statutory override — creating a commercially-driven generic entry opportunity.

Connection to this news: The Novo Nordisk patent lapse in Canada illustrates how even without compulsory licensing, procedural patent failures can open markets prematurely — and Indian generic manufacturers like Dr. Reddy's are positioned to capture such first-mover windows globally.

Key Facts & Data

Dr. Reddy's received Health Canada Notice of Compliance (NOC): April 29, 2026.
Canada: first G7 country to approve generic semaglutide.
Drug: semaglutide injection — active ingredient in Ozempic (diabetes) and Wegovy (obesity).
Approved dosage: 2 mg/pen and 4 mg/pen (1.34 mg/mL).
Branded Ozempic price in Canada: ~CAD 450/month; generic expected at CAD 40–80/month.
India pharma exports: USD 30.38 billion in FY25.
India = world's largest generic drug supplier by volume (~20% of global volume).
India supplies ~45% of US FDA-regulated generic drug demand by volume.
India imports ~70% of APIs from China — key supply chain vulnerability.
API PLI scheme outlay: ₹6,940 crore.
TRIPS Agreement: 20-year patent protection, with Doha Declaration flexibilities for public health.
India's Section 3(d), Patents Act: bars "evergreening" of pharmaceutical patents.
Type 2 diabetes patients in India: over 100 million (world's highest).